Drug Trial Radar · NCT07349537
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
574
Planned (sponsor's estimate)
Start
Jan 8, 2026
Primary completion
Apr 2028
Study completion Oct 2028
Sponsor
- Lead sponsor
- Revolution Medicines, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of RMC-5127 as a monotherapy and in combination with either daraxonrasib or cetuximab in adults with KRAS G12V-mutant solid tumors.
Conditions
- Non-small Cell Lung Cancer (NSCLC)
- Colorectal Cancer (CRC)
- Pancreatic Adenocarcinoma
- Pancreatic Ductal Adenocarcinoma (PDAC)
- PDAC
- CRC
- NSCLC
- Pancreatic Cancer
- Lung Cancer (NSCLC)
- Advanced Solid Tumors
Interventions
RMC-5127Drug
oral tablets
daraxonrasibDrug
oral tablets
cetuximabDrug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with adverse events (AEs)Time frame: Up to approximately 3 years
- Changes in vital signsTime frame: Up to approximately 3 years
- Changes in electrocardiogram (ECG) test valuesTime frame: Up to approximately 3 years
- Changes in clinical laboratory test valuesTime frame: Up to approximately 3 years
- Dose Limiting ToxicitiesTime frame: Up to 28 days
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Yale Cancer Center
New Haven, Connecticut · Recruiting
Johns Hopkins
Baltimore, Maryland · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
Laura and Isaac Perlmutter Cancer Center at NYU Langone Health
New York, New York · Recruiting
NEXT - Dallas
Dallas, Texas · Recruiting
NEXT
San Antonio, Texas · Recruiting
START - San Antonio
San Antonio, Texas · Recruiting
NEXT - Virginia
Fairfax, Virginia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.